Cardiovascular Benefits of New Antidiabetic Drug Classes: A Network Meta-analysis

Login or register to view PDF.
Creative Commons Licence
 
Received date
14 May 2020
Accepted date
14 May 2020
Citation
European Cardiology Review 2020;15:e40.
DOI
https://doi.org/10.15420/ecr.2020.15.1.PO17
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Aim: New antidiabetic drugs are required to be evaluated in cardiovascular outcome trials (CVOTs). Few of these are direct comparisons between new drugs, so we performed a network meta-analysis to compare the new drug classes in terms of cardiovascular outcomes.

Method: We searched for CVOTs involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes using major adverse cardiovascular events (MACE) and mortality as endpoints. Network meta-analysis was performed using random-effects model in R.

Results: 13 CVOTs with a total 116,746 patients were included (Figure 1). GLP-1 RAs and SGLT-2 inhibitors significantly lowered the risk of MACE (OR 0.87, 95% CI [0.82–0.94] and OR 0.89, 95% CI [0.82–0.97]), all-cause mortality (OR 0.90, 95% CI [0.82–0.99] and OR 0.84, 95% CI [0.76–0.93]), heart failure (OR 0.87, 95% CI [0.82–0.93] and OR 0.70, 95% CI [0.62–0.80]), and renal composite outcome (OR 0.85, 95% CI [0.75–0.97] and OR 0.63, 95% CI [0.55–0.72]) when compared to placebo (Figure 2). GLP-1 RAs reduced nonfatal stroke (OR 0.88, 95% CI [0.77–0.99]), while SGLT-2 inhibitors reduced cardiovascular mortality (OR 0.83, 95% CI [0.72–0.96]). In contrast, DPP-4 inhibitors did not significantly alter the risk of these outcomes.

Conclusion: GLP-1 RAs and SGLT-2 inhibitors both reduce MACE, heart failure, renal composite outcome, and all-cause mortality when compared to placebo. DPP-4 inhibitors did not show any cardiovascular benefits. Our findings support using SGLT-2 inhibitors and GLP-1 RAs for diabetic patients with high cardiovascular risk.

Cardiovascular Benefits of New Antidiabetic Drug Classes

Open in new tab
Open ppt

Cardiovascular Benefits of New Antidiabetic Drug Classes

Open in new tab
Open ppt